JP2024537827A - 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びｈｉｖにおけるそれらの使用方法 - Google Patents

抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びｈｉｖにおけるそれらの使用方法 Download PDF

Info

Publication number
JP2024537827A
JP2024537827A JP2024519822A JP2024519822A JP2024537827A JP 2024537827 A JP2024537827 A JP 2024537827A JP 2024519822 A JP2024519822 A JP 2024519822A JP 2024519822 A JP2024519822 A JP 2024519822A JP 2024537827 A JP2024537827 A JP 2024537827A
Authority
JP
Japan
Prior art keywords
specifically binds
chain variable
variable region
hiv protein
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537827A5 (enExample
Inventor
ロニー ロン ウェイ
リン シュ
ジー－ヨン ヤン
ゲイリー ジェイ． ナベル
Original Assignee
モードエックス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モードエックス セラピューティクス インコーポレイテッド filed Critical モードエックス セラピューティクス インコーポレイテッド
Publication of JP2024537827A publication Critical patent/JP2024537827A/ja
Publication of JP2024537827A5 publication Critical patent/JP2024537827A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024519822A 2021-09-29 2022-09-28 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びｈｉｖにおけるそれらの使用方法 Pending JP2024537827A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163249722P 2021-09-29 2021-09-29
US63/249,722 2021-09-29
PCT/US2022/077203 WO2023056315A1 (en) 2021-09-29 2022-09-28 Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv

Publications (2)

Publication Number Publication Date
JP2024537827A true JP2024537827A (ja) 2024-10-16
JP2024537827A5 JP2024537827A5 (enExample) 2026-01-20

Family

ID=85783606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519822A Pending JP2024537827A (ja) 2021-09-29 2022-09-28 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びｈｉｖにおけるそれらの使用方法

Country Status (13)

Country Link
US (1) US20250197481A1 (enExample)
EP (1) EP4408892A4 (enExample)
JP (1) JP2024537827A (enExample)
KR (1) KR20240099226A9 (enExample)
CN (1) CN118660907A (enExample)
AR (1) AR127176A1 (enExample)
AU (1) AU2022357501A1 (enExample)
CA (1) CA3232365A1 (enExample)
CL (1) CL2024000890A1 (enExample)
IL (1) IL311762A (enExample)
MX (1) MX2024003804A (enExample)
TW (1) TW202325744A (enExample)
WO (1) WO2023056315A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
WO2025162460A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 一种轭合化合物及其制备和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX353382B (es) * 2012-03-01 2018-01-10 Amgen Res Munich Gmbh Moleculas de union polipeptido de larga duracion.
US9458244B2 (en) * 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
RS62437B1 (sr) * 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
CA3020633A1 (en) * 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
WO2018075564A1 (en) * 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
US12365722B2 (en) * 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
AU2019372673A1 (en) * 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白

Also Published As

Publication number Publication date
KR20240099226A9 (ko) 2025-12-10
CN118660907A (zh) 2024-09-17
IL311762A (en) 2024-05-01
AU2022357501A1 (en) 2024-04-18
EP4408892A4 (en) 2025-11-19
CA3232365A1 (en) 2023-04-06
WO2023056315A1 (en) 2023-04-06
KR20240099226A (ko) 2024-06-28
AR127176A1 (es) 2023-12-27
MX2024003804A (es) 2024-06-11
EP4408892A1 (en) 2024-08-07
US20250197481A1 (en) 2025-06-19
CL2024000890A1 (es) 2024-10-11
TW202325744A (zh) 2023-07-01

Similar Documents

Publication Publication Date Title
EP3414266B1 (en) Broadly neutralizing antibodies against hiv-1 and use thereof
EP3365366B1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
AU2015295936B2 (en) Anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
CN114341186B (zh) 双特异性抗LRRC15和CD3ε抗体
BR112021002032A2 (pt) construtos de anticorpos para cldn18.2 e cd3
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
US20250368722A1 (en) Multispecific antibodies targeting multiple epitopes on the hiv-1 envelope
JP2024537804A (ja) 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びそれを使用する方法
JP7099709B2 (ja) ヒト化抗ベイシジン抗体およびその使用
AU2017292752B2 (en) Antibodies with low immunogenicity and uses thereof
US20050288492A1 (en) Anti-activated RAS antibodies
JP2024537827A (ja) 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びｈｉｖにおけるそれらの使用方法
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
BR112020023432A2 (pt) molécula de ligação a gp41, composição farmacêutica e método para tratar ou prevenir infecção por hiv-1 em um indivíduo que precisa do mesmo
IL317895A (en) Anti-SARS-COV-2 antigen-binding polypeptides, polypeptide complexes and methods of using them
JP2025500918A (ja) Ｔｎｆｓｆリガンドの細胞外ドメインを含有する抗原結合ポリペプチド複合体
CN114751988B (zh) 中和冠状病毒的多特异性抗体
WO2024007013A2 (en) Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof
WO2024123897A1 (en) Broadly neutralizing and potent antibodies against hiv
WO2025256479A1 (zh) 一种融合蛋白及其用途
HK40118288A (zh) 包含结合γ-δ T细胞受体的抗体的组合物
HK1253385B (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260109